Palo Alto · Seed–Late Stage · 6 people tracked
Also known as SAMSARA BIOCAPITAL, LLC
Investment thesis
Samsara BioCapital invests in the creation of transformative therapeutics for patients. The firm assembles a team of scientists, physicians, drug developers, and business leaders with hundreds of years of combined experience to back the next generation of therapeutic breakthroughs. Its ethos draws inspiration from Darwin's ideas on evolution and the branching Tree of Life, emphasizing scientific rigor and the potential for new therapeutic ideas to grow and diverge over time.
Source: firm website, verified Aug 25, 2026.
Team · 6 people
from public directories
What they invest in
from 65 of 93 portfolio companiesBiotech ×62Healthtech ×37Medical Devices ×26Deep Tech ×14Digital Health ×10AI & Machine Learning ×7Developer Tools ×1Fintech ×1
HQs:United States×48Canada×1China×1
Who they back
founder profiles across 26 portfolio companiesFounding team size:solo founder×112 founders×73 founders×54+ founders×3
Investments · 93 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 52024 · 62023 · 22022 · 12020 · 22019 · 22018 · 22017 · 32015 · 127 dated
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Board seatSrini Akkaraju· per SEC Form D · $45.8M raise · filed Sep 2017
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesDomain PartnersPolaris Partners
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)Adam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAndera PartnersSR One Capital ManagementYsios CapitalBoulder VenturesCatalys PacificRA Capital
Accelerating development of new genetic medicines for people with devastating neurological diseases.
New York, US
Rachel McMinn(Executive Officer, Director)in
BoardCory Freedland(Director)Stephen Biggar(Director)
Board seatRobert Baffi· per SEC Form D
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inPaul J. Hastings(Chief Executive Officer)Matthew Plunkett(Executive Officer)
BoardJill Carroll(Director)
Board seatMichael Dybbs· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)SR One Capital ManagementNorwest Venture Partners
Clinical-stage company developing next generation antibody drug conjugates for cancer treatment using proprietary cell-free protein manufacturing technology.
BiotechSouth San Francisco, US
William J. Newell(Executive Officer, Director)Joseph Lobacki(Director)Virgil Bryan Lawlis(Director)Michael Ross(Director)Daniel Petree(Director)
BoardDaniel Janney(Director)
Board seatMichael Bryan Dybbs· per SEC Form D
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.
BiotechDigital HealthMedical DevicesHigh Point, US
Rudy Howard(Executive Officer)Stephen Holcombe(Executive Officer)Larry Altstiel(Executive Officer)Jeffrey Kindler(Executive Officer, Director)Paul Meister(Director)Paul Savas(Director)
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsJDRF T1D Fund
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Co-investorsARCH Venture PartnersThird Rock VenturesFlagship Ventures
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)
Co-investorsForesite CapitalNextech InvestOrbiMedSR One Capital ManagementvenBio PartnersWestlake Village BioPartners+1 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsRA CapitalSofinnova VenturesVivo CapitalNan Fung Life SciencesNovo Holdings+1 more
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)
Co-investorsHadean VenturesRed Tree VentureCasdin CapitalFranklin TempletonSectoral Asset Management
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Joshua Bilenker, M.D.(Director)
Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)
Developing a best-in-class approach for neovascular retinal diseases.
Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.
Rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments.
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)David Liu(Co-founder)Allan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)Ann Lee(Chief Technical Officer)Svetlana Makhni(Chief Financial Officer)
Co-investorsARCH Venture PartnersGV (Google Ventures)Newpath PartnersF-Prime CapitalOUP (Osage University Partners)
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Alan Buckler(Executive Officer)
BoardAmir Nashat(Director)in
Co-investorsARCH Venture PartnersPolaris Partners
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.
BiotechHealthtechMedical DevicesAliso Viejo, US
Malik Kahook(Executive Officer, Director)inGlenn Sussman(Co-founder)inMalik Y. Kahook(Co-founder)inPatrick Mooney(CEO)
BoardJake Merrill(Director)Geoff Pardo(Director)
Co-investorsNew Enterprise Associates (NEA)RA CapitalVensana Capital
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)Aaron Deykin(Chief Medical Officer & Head of R&D)Mike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)Stacy Price(Chief Technology Officer)
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalTCG Crossover+1 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatMichael Dybbs· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSanofi VenturesMass General Brigham VenturesREDMILE+8 more
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardJay Lichter(Director)Tighe Reardon(Executive Officer)
Board seatMarcos Milla· per SEC Form D
Co-investorsFrazier Life SciencesLightspeed Venture PartnersAvalon BioVenturesPappas CapitalPfizer Venture InvestmentsOrbiMed
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsLongitude CapitalAscenta CapitalF-Prime Capital
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.
BiotechHealthtechMedical DevicesChanhassen, US
Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)William Davis(Executive Officer, Director)
BoardKlaus Veitinger(Director)inImran Eba(Executive Officer)in
Co-investorsOrbiMedHealthQuest CapitalSV Health InvestorsAction Potential Venture Capital Ltd.
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in
Co-investorsARCH Venture PartnersEcoR1 Capital6 Dimensions CapitalGeneral CatalystInnovation EndeavorsLeaps by Bayer+5 more
Link Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors.
BiotechHealthtech
Robbie MajznerCrystal MackallJerry Cacia(Chief Operating Officer)Mark Wallet(Chief Scientific Officer)
Co-investorsWing
Lumen develops orally delivered antibody drugs using engineered spirulina, a patented biologic platform that reduces manufacturing costs and timelines compared to conventional biologics.
BiotechDeep TechHealthtechMedical DevicesSeattle, US
Co-investorsWestRiver Group
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)Lieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)William LaRochelle(Chief Scientific Officer)Stacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesCanaan PartnersConnecticut InnovationsPfizer Venture Investments+3 more
PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery.
AI & Machine LearningBiotechDeep Tech
Co-investorsLightstone Ventures
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)Martin Oft(Chief Scientific Officer)Naiyer Rizvi(Chief Medical Officer)Gregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsThe Column GroupBain Capital Life SciencesCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.
BiotechDeep TechHealthtechMedical Devices
BoardSrini Akkaraju(Director, Founder)Paul Kang(Director, Founder)
Co-investorsVersant Ventures
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
C. Alexander Kamb(Director)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardDavid Goeddel(Director)
Board seatSrini Akkaraju· per SEC Form D
Co-investorsNextech InvestVida VenturesThe Column Group
Seattle, US
Eric Dobmeier(Executive Officer, Director)Sam Hall(Director)
BoardJeremy Caldwell(Director)Jerel Davis(Director)in
Board seatSrinivas AkkarajuSrini Akkaraju· per SEC Form D · $115M raise · filed Oct 2020
Co-investorsVersant Ventures
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Executive Officer, Director, Promoter)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)in
BoardRishi Gupta(Director)in
Board seatMichael Dybbs· per SEC Form D
Co-investorsAV8 VenturesForesite CapitalIllumina VenturesMenlo VenturesOpen Field CapitalOrbiMed+3 more
HealthtechSan Francisco, US
June Lee(Executive Officer, Director)
BoardJames Tananbaum(Director)Vikram Bajaj(Director)
Board seatSrinivas Akkaraju· per SEC Form D · $40M raise · filed Jul 2024
Co-investorsForesite Capital
BiotechSeattle, US
Erik Anderson(Director)Mark Litton(Director)Robert Carlson(Director)Craig Behnke(Executive Officer)Ed Schlect(Director)John Morrow(Executive Officer)
Board seatMarcos Milla· per SEC Form D · $23M raise · filed Apr 2025
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)
BoardPETER THOMPSON(Director)SIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Board seatSrinivas AkkarajuMichael Dybbs· per SEC Form D · $50M raise · filed Sep 2018
Co-investorsAccess BiotechnologyMission BiocapitalSofinnova VenturesMission Bay CapitalNew Leaf Venture PartnersOrbiMed
Cambridge, MA gene-control biopharma that developed tamibarotene for RARA-overexpressing blood cancers; now in wind-down.
Cambridge, US
Board seatSrinivas Akkaraju· per SEC Form D · $11.4M raise · filed Feb 2018
Co-investorsARCH Venture PartnersPolaris Partners
A2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Jim Robinson(CEO)
Co-investorsThe Column Group
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersClaret Capital PartnersMedicxiSofinnova PartnersTruffle Capital
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsDecheng CapitalvenBio Partners
BiotechRedwood City, US
Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)
Co-investorsFrazier Life Sciences5AM VenturesVenrock Healthcare Capital PartnersVivo Capital
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope).
BiotechDeep TechHealthtechFremont, US
Yuling Luo(Co-founder, CEO and Chair)Steve Chen(Co-founder, COO and Director)Yiyuan Yin(Co-founder, VP of Technology)Tod White(President)Justin McAnear(CFO)inXiao-Jun Ma(CTO)
Co-investorsIllumina VenturesQiming Venture Partners
Developing therapies to reverse goblet cell hyperplasia for cystic fibrosis and other pulmonary conditions.
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersRoche Venture Fund
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
Developing sonodynamic therapy for brain cancer.
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSixty Degree CapitalSolasta VenturesSR One Capital Management+2 more
Accelerates the translation of novel science to realize the potential of academic research.
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsNewpath Partners
Co-investorsAlta PartnersARCH Venture PartnersDC Investment PartnersLongwood FundNextech InvestPathway to Cures+6 more
Developing technology focused on restoring sight to patients with advanced-stage blindness due to retinal degenerative diseases.
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedTCG CrossoverThird Rock VenturesvenBio PartnersVida Ventures
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)Anup Radhakrishnan(Executive Officer)Cassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny VentureThird Rock Ventures
Co-investorsScion Life SciencesVersant Ventures
BiotechJersey City, US
Henry Rath(Executive Officer)Susan Orr(Executive Officer)Clarke Atwell(Executive Officer, Director)Stephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)
Co-investorsCatalio Capital ManagementNovo HoldingsSofinnova Ventures
Develops clinical intelligence solutions for healthcare providers to enable data-driven decision making in healthcare workflows.
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsLongwood FundSofinnova VenturesBAM ElevateFinchley Healthcare VenturesForbionLuma Group+1 more
Originator of Otarmeni (lunsotogene parvec-cwha), an FDA-approved gene therapy for genetic hearing loss; acquired by Regeneron in 2023.
Cambridge, US
Co-investorsage1Third Rock Ventures
Clinical-stage biopharmaceutical company combining innovative chemistry with validated biology to make medicines more accessible for chronic autoimmune and inflammatory diseases.
Co-investorsOUP (Osage University Partners)
ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.
BiotechDeep TechHealthtechWaltham, US
David Hallal(CEO)Mike Paglia(Chief Technology Officer)Ger Brophy(CEO)
Co-investorsEcoR1 CapitalMPM BioImpactSoftBank Vision Fund
Developing therapies targeting Dark Antigens, a novel class of cancer-specific targets from genomic dark matter.
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundTaiho Ventures, LLC+3 more
Developing best-in-class protein therapeutics for rapidly relieving or preventing allergic-mediated diseases.
Co-investorsRed Tree Venture
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupCasdin CapitalNovartis Venture Fund
Clinical-stage ophthalmology biotech company delivering a next-generation pipeline for back-of-the-eye diseases, acquired by Merck in 2024.
Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries.
BiotechDeveloper Tools
Co-investorsCivilization Ventures Management, LlcCota CapitalIllumina Ventures
Clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare hematologic diseases and cancers, acquired by Novo Nordisk in 2022.
Genalyte develops Merlin, a real-time diagnostic system that performs laboratory testing directly in clinical settings and integrates results with electronic health records.
Digital HealthHardwareHealthtechMedical DevicesSan Diego, US
Cary Gunn(Co-founder and Chief Technical Officer)
Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesFusionX VenturesIPD CapitalSeed Healthcare+3 more
BiotechFintech
Co-investorsCatalys PacificFrazier Life SciencesLightspeed Venture PartnersRA Capital
Immunovirology company harnessing science at the intersection of immunology and virology to design broad therapeutics with durable response across multiple viruses.
Intercept Pharma develops therapeutics for rare liver diseases, focusing on cholestatic pruritus in Primary Biliary Cholangitis patients through IBAT inhibitor programs and bile acid biology research.
BiotechHealthtechMedical Devices
Co-investorsAisling CapitalBioBritRidgeback Capital
Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.
BiotechMedical Devices
Co-investorsEuropean Investment BankAndera PartnersClaret Capital PartnersNew Enterprise Associates (NEA)Sofinnova PartnersBiotechnology Value Fund+1 more
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsAvoro Capital AdvisorsEIR VenturesKurma PartnersRA CapitalSunstone CapitalVivo Capital+2 more
Co-investorsAvoro Capital AdvisorsVivo Capital
Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases.
BiotechMedical DevicesLa Jolla, US
David Campbell, Ph.D.(Executive Officer, Director)Tighe Reardon(Executive Officer)
BoardJay Lichter, Ph.D.(Director)Jake Simson, Ph.D.(Director)Peter Thompson, M.D.(Director)Stefan Heller(Director)
Co-investorsAvalon BioVenturesOrbiMed
Developing breakthrough logic-gate technology to enable CAR-T development for patients with solid tumors.
Platform company developing new agents for hematologic diseases.
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)
BoardZach Scheiner(Director)inMegan Krench(Director)Dmitrij Hristodorov(Director)in
Co-investorsSanofi VenturesAvego BioScience CapitalForbionRA Capital
A therapeutics company developing checkpoint agonist antibodies for autoimmune disease treatment based on Oxford University research (exited August 2022).
Co-investorsAdvent Life SciencesMedicxiMonograph Capital PartnersOxford Science Enterprises
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)PAUL ROGERS(Executive Officer)
BoardDAVID ALLISON(Director)
Co-investors5AM VenturesOrbiMedvenBio PartnersVivo CapitalvenBio Global StrategicWestlake Village BioPartners
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)Zhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalLAVLilly Asia VenturesRA CapitalThe Innovation SpaceLogos
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsThe Column GroupSanofi Ventures
Engaged in discovery and development of targeted small molecule therapies for cancer treatment, including selective mutant-specific PI3K inhibitors.
BiotechBoulder, US
Anthony D. Piscopio(Executive Officer, Director)Nicholas Saccomano(Director)Duncan Walker(Executive Officer)James Winkler(Executive Officer)Jason Leverone(Executive Officer)Keith M. Olivia(Executive Officer)
Co-investorsACORN BIOVENTURES
Developing first-in-class, one-of-a-kind PD-1/VEGFR2 dual pathway antibodies to extend lives of people living with cancer.
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
BiotechHealthtechResearch Triangle Park, US
BT Slingsby(Co-Founder & Executive Chairman)
Co-investorsAbingworthCatalys PacificOrbiMedKB Investment
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
James R Appleman(Executive Officer, Director)James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)Stephen Webber(Vice President, Medicinal Chemistry, and Cofounder)Paulo S Rangel(Executive Officer, Director)Charles McDermott(President & CEO, Director)
Co-investorsBioBritBioRock VenturesPolaris Partners
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsScion Life SciencesSofinnova VenturesTCG CrossovervenBio PartnersVersant VenturesVivo Capital+1 more
Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension.
BiotechDigital HealthHealthtechMedical Devices
John Kollins(Chief Executive Officer)
Co-investorsCottonwood Technology Fund
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)Elizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)
Co-investorsCatalio Capital Management, LPRA CapitalVertex Ventures HCThird Rock Ventures
Developing next-generation chemical inducers of proximity to hijack cancer drivers as cancer cures.
Biotechnology company focused on therapeutic development.
Creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.
BiotechLa Jolla, US
Alyssa Lochbaum(Executive Officer)Paul Kang(Director)Paul Grayson(Executive Officer, Director)
BoardCory Freedland(Director)Jerel Davis(Director)Srinivas Akkaraju(Director)
HealthtechSan Diego, US
Kenneth Song, M.D.(Executive Officer, Director)
Co-investorsForesite CapitalQiming Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 25
IPOs and acquisitions across the tracked portfolioaTYR PHARMANASDAQ: ATYRMineralys TherapeuticsNASDAQ: MLYSNeurogene IncNASDAQ: NGNENkarta, Inc.NASDAQ: NKTXSutro BioPharma, Inc.NASDAQ: STROVtvtherapeuticsNASDAQ: VTVTAgios PharmaceuticalsNASDAQ: AGIOAlumisNASDAQ: ALMSBolt BiotherapeuticsNASDAQ: BOLTContineum TherapeuticsNASDAQ: CTNMGossamer BioNASDAQ: GOSSKalaris Therapeutics, Inc.NASDAQ: KLRSLENZ Therapeutics, Inc.NASDAQ: LENZPalvella Therapeutics, Inc.NASDAQ: PVLAPrime MedicineNASDAQ: PRMEScholar Rock Holding Corp, Inc.NASDAQ: SRRKSpyglass PharmaNASDAQ: SGPUpstream BioNASDAQ: UPBAcelyrinacq. by AlumisDecibel Therapeuticsacq. by RegeneronExcellergy Therapeuticsacq. by NovartisEyebiotech Limitedacq. by MerckForma Therapeuticsacq. by Novo NordiskHilleVaxacq. by XOMA RoyaltyIntercept Pharmaceuticalsacq. by Alfasigma
Portfolio news
latest coverage across their companiesNeurogene Inc · americanbankingnews.com · Aug 27, 2026
Inventiva · themarketsdaily.com · Aug 26, 2026
Contineum Therapeutics · stocktitan.net · Aug 25, 2026
Abcuro · clinicaltrialsarena.com · Aug 19, 2026
Mineralys Therapeutics · mychesco.com · Aug 18, 2026
Nkarta, Inc. · marketbeat.com · Aug 17, 2026
Arcellx · biobuzz.io · Aug 14, 2026
Frequently asked questions
- How many investments has Samsara BioCapital made?
- Samsara BioCapital has 73 tracked investments, 10 of which have exited via acquisition or IPO, including 4 dated in the last 24 months.
- What stage does Samsara BioCapital invest at?
- Samsara BioCapital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Samsara BioCapital focus on?
- Samsara BioCapital focuses on Biotech, Healthtech, Medical Devices.
- Where is Samsara BioCapital located?
- Samsara BioCapital is headquartered in Palo Alto, US.
- Who does Samsara BioCapital co-invest with?
- Samsara BioCapital most often shares deals with RA Capital, New Enterprise Associates (NEA), Vivo Capital, among 100 tracked co-investors.
Co-investors · 18
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
.png)
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
▶6 more co-investors
Advent Life SciencesLightstone VenturesEQT Life SciencesFlagship PioneeringGenoa VenturesAmplitude Venture Capital
Firms observed investing alongside Samsara BioCapital, from public investor directories. Shared companies are the overlap with Samsara BioCapital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.